Prosensa Holding B.V. (RNA) 18.65 $RNA Prosensa

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Prosensa Holding B.V. (RNA) 18.65 $RNA

Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution
GlobeNewswire - Tue Feb 10, 11:16AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company", the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that, on February 11, 2015, it will file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act" (the "Form 25", with the Securities Exchange Commission ("SEC" in order to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares" from the NASDAQ Global Select Market ("NASDAQ", which will become effective 10 days after filing. NASDAQ has advised the Company that it will suspend trading of the Shares after the market closes on February 11, 2015. As such, shareholders of the Company will not be able to trade their shares on NASDAQ thereafter.
BMRN: 89.88 (-1.61), RNA: 18.65 (unch)

Prosensa Announces Intent to Voluntarily Delist From NASDAQ
GlobeNewswire - Fri Jan 30, 7:36AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company", the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that it intends to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares", from the NASDAQ Global Select Market ("NASDAQ". Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to deregister the Shares under the Securities Exchange Act of 1934, as amended (the "Exchange Act" and to suspend its reporting obligations under the Exchange Act once it is eligible to do so.
BMRN: 89.88 (-1.61), RNA: 18.65 (unch)

BioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period
GlobeNewswire - Fri Jan 30, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the final results of, and the completion of the subsequent offering period relating to, the previously announced tender offer by its subsidiaries, BioMarin Falcons B.V. and BioMarin Giants B.V. (together, "Purchaser", to acquire all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA) at a purchase price of $17.75 per share, net to the seller in cash (the "Cash Consideration", plus one non-transferrable contingent value right to receive cash payments of up to $4.14 per share in the aggregate upon the achievement of certain product approval milestones ("CVR", in each case, without interest thereon and less any applicable withholding taxes.
BMRN: 89.88 (-1.61), RNA: 18.65 (unch)

BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 5:00PM CST
BioMarin (BMRN) will be raising approximately $792.6 million through the issuance of the shares in order to finance the Prosensa acquisition.
BMRN: 89.88 (-1.61), RNA: 18.65 (unch), ALXN: 125.67 (+1.25), AMGN: 160.74 (-0.36)

3 Warning Signs You've Invested in a Dangerous Biotech Stock
Motley Fool Staff - Motley Fool - Sat Jan 17, 10:59AM CST
Source: Flickr user  epSos .de . There might not be a bell that will ring to alert investors when they have put their money in the wrong biotech stock, but there are warning signals that can help them avoid owning the most dangerous biotech...
INO: 9.33 (+0.22), BMRN: 89.88 (-1.61), RNA: 18.65 (unch), GSK: 43.72 (+0.34)

BioMarin Announces Completion of Tender Offer for Prosensa's Shares and Commences Subsequent Offering Period
GlobeNewswire - Thu Jan 15, 7:59AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it completed the initial offering period for the previously announced tender offer for all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA). As a result, BioMarin will purchase approximately 93.4% of Prosensa's outstanding shares pursuant to the initial offering period for the tender offer. BioMarin also announced that it has commenced a subsequent offering period to provide Prosensa shareholders who have not yet tendered their shares the opportunity to do so. The subsequent offering period is scheduled to expire at 6:00 p.m., New York City time, on January 29, 2015.
BMRN: 89.88 (-1.61), RNA: 18.65 (unch)

BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:10PM CST
BioMarin (BMRN) raised its 2014 guidance for Vimizim sales and presented encouraging interim data from an ongoing phase I/II pivotal study on Batten disease candidate, BMN 190.
BMRN: 89.88 (-1.61), RNA: 18.65 (unch), ALXN: 125.67 (+1.25), AMAG: 25.88 (+0.69)

Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer
GlobeNewswire - Tue Jan 13, 7:56AM CST
Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that during an extraordinary general meeting of shareholders held today, Prosensa obtained shareholder approval for certain matters relating to the previously disclosed tender offer by BioMarin to purchase all of the outstanding shares of Prosensa.
RNA: 18.65 (unch)

Why Sarepta Therapeutics Inc. Stock Tumbled 15% in December
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 6:04AM CST
SRPT data by YCharts What: Shares of Sarepta Therapeutics , a clinical-stage biotechnology company primarily focused on developing therapies to treat Duchenne muscular dystrophy, or DMD, tumbled 15% in December according to data from ...
BMRN: 89.88 (-1.61), RNA: 18.65 (unch), SRPT: 22.70 (+0.08)

PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.65 (unch), SRPT: 22.70 (+0.08), PTCT: 7.61 (+0.08), BIOD: 0.30 (-0.01)

BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa
GlobeNewswire - Wed Dec 24, 12:15PM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act", which occurred at 11:59 p.m. on December 23, 2014, with respect to BioMarin's pending acquisition of Prosensa.
BMRN: 89.88 (-1.61), RNA: 18.65 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 455

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 501

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 431

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 427

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 305

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 631

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring AI's Transformative Impact on Global Filmmaking

Updated Category News Views 171

The Future of Filmmaking in the Age of AI The Short Shorts Film Festival & Asia (SSFF & ASIA) recently hosted an engaging conference focused on how artificial intelligence is revolutionizing the filmmaking process. This Academy Award–qualifying festival has become a significant platform for showcasing short films from around the globe. During the event, titled 'The...

Continue Reading
Darkex Launches Revolutionary Crypto Trading Platform Today

Updated Category News Views 365

The Launch of the Darkex Cryptocurrency Trading Platform The long-awaited cryptocurrency exchange, Darkex, has officially launched, promising a top-notch trading experience for both retail and institutional investors. With a strong focus on security, innovation, and user-friendly services, Darkex aims to reshape the cryptocurrency trading landscape. Setting a New...

Continue Reading
Understanding the Saver's Credit: A Key to Retirement Savings

Updated Category News Views 187

The Importance of the Saver's Credit for Retirement Savers The Saver's Credit is a valuable resource for many individuals aiming to bolster their retirement savings while easing their tax burdens. Recent findings reveal that over half of U.S. workers remain unaware of this advantageous tax credit designed to aid retirement savers. Understanding this credit can empower...

Continue Reading
Why Stock Splits Matter: Insights on Major Tech Players

Updated Category News Views 190

Stock splits became a hot topic in the investment world during 2024, with companies like Nvidia and Sony Group making headlines. Traders were on high alert as these maneuvers shifted market dynamics. A stock split isn’t just a cosmetic change; it’s a tactical play that can signal confidence from management, but does it really move the needle for investors? Let’s...

Continue Reading
Accelerating Growth in Global Dry Film Photoresist Market

Updated Category News Views 177

Global Dry Film Photoresist Market Overview The dry film photoresist market is primed for substantial growth as it experiences increased demand across various industries. This market is characterized by its segmentation into types, namely positive and negative dry film photoresists, and applications including PCB manufacturing and semiconductor packaging. Projections...

Continue Reading